News
- Author:
- Jeff Craven
Publish date: December 17, 2019
In two validation cohorts, the criteria had specificities of 97.8%-99.2% and sensitivities of 82.0%-85.5%.
News
- Author:
- Jeff Craven
Publish date: December 12, 2019
ATLANTA – When Raynaud’s phenomenon is present, risk for progression is best predicted by the presence of puffy fingers, disease-specific antibodie...
News
- Author:
- Jeff Craven
Publish date: December 11, 2019
ATLANTA – The phase 3 trial looked at flare rate out to 44 weeks after patients first met response criteria following 18 weeks of open-label treatm...
News
- Author:
- Jeff Craven
Publish date: December 9, 2019
ATLANTA – Just 1.2% of patients taking biologics with negative tuberculosis test results converted to positive results in annual tuberculosis scree...
News
- Author:
- Jeff Craven
Publish date: December 9, 2019
Higher lipoprotein(a) molar concentration is linked to an increased risk of cardiovascular disease, compared with apolipoprotein(a) size.
News
- Author:
- Jeff Craven
Publish date: December 9, 2019
ATLANTA – A higher Charlson Comorbidity Index and longer surgery time, rather than preop antirheumatic medications, increased risk of infection.
News
- Author:
- Jeff Craven
Publish date: November 25, 2019
ATLANTA – More safety events were seen with the higher 5-mg dose than with 2.5 mg.
News
- Author:
- Jeff Craven
Publish date: November 24, 2019
ATLANTA – “For any individual patient, a single option may be chosen at a particular time point, perhaps with or without other options, and may be ...
News
- Author:
- Jeff Craven
Publish date: November 22, 2019
PHILADELPHIA – It has a very low adverse event profile and is well tolerated.
News
- Author:
- Jeff Craven
Publish date: November 21, 2019
ATLANTA – Mortality of people with systemic sclerosis in the United States aged 44 and younger now rivals the death rate for the general population...
News
- Author:
- Jeff Craven
Publish date: November 18, 2019
PHILADELPHIA – “There’s a major opportunity for us at the onset of menopause to identify risks and initiate preventive strategies.”
News
- Author:
- Jeff Craven
Publish date: November 17, 2019
Cancer or cancer-related treatments were covered by 41% of programs, and 34% provided assistance for genetic or rare diseases.
News
- Author:
- Jeff Craven
Publish date: November 15, 2019
ATLANTA – The trial of 555 patients “is the largest study done for a biologic agent in nonradiographic axial spondyloarthritis,” said Dr. Atul A. D...
News
- Author:
- Jeff Craven
Publish date: November 13, 2019
PHILADELPHIA – Patients had similar fibroid treatment benefits despite different baseline characteristics.
News
- Author:
- Jeff Craven
Publish date: November 12, 2019
ATLANTA – The alert system led to increased decisions to escalate or deescalate therapy.
